U.S. BIOSCIENCE CYTOPROTECTIVE AGENT ETHYOL's EFFICACY NOT CONFIRMED BY NEW COHORT, ADVISORY CMTE. CONCLUDES; USB WILL CONTINUE DEVELOPMENT OF DRUG
Executive Summary
U.S. Bioscience's Ethyol cytoprotective agent's efficacy in reducing neutropenia-associated events, seen in the original 121- patient study cohort, was not confirmed in a new cohort of 121 additional ovarian cancer patients, FDA Oncologic Drugs Advisory Committee concluded Dec. 12 during its second review of the drug.